Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) reports developments tied to its transition from a biotechnology-focused company toward a diversified, revenue-generating operating model. Company news has covered material agreements involving cardiovascular drug candidates, licensing activity for acute pulmonary treatments, patent estate updates for istaroxime and SERCA2a activators, and clinical or regulatory disclosures related to heart failure and surfactant-based programs.
Recurring updates also include stockholder approvals, governance matters, capital actions, OTC trading status, and operating and financial results. Windtree’s disclosed product and license references include SURFAXIN®, lyophilized lucinactant, and AEROSURF®, a drug-device combination based on aerosolized KL4 surfactant delivery.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Windtree Therapeutics (NasdaqCM: WINT) has released findings from the SEISMiC Study, demonstrating that istaroxime significantly improves systolic blood pressure (SBP) in patients with early cardiogenic shock due to heart failure. The study showed a 93.6% relative increase in SBP AUC over the first 6 hours with the 1.0 μg/kg/min dose, compared to a 39.5% increase with the higher dose of 1.5 μg/kg/min. Importantly, istaroxime therapy did not worsen renal function. These results were published in the Journal of Cardiac Failure, highlighting the drug's potential as a first-in-class treatment for acute heart failure conditions. Dr. Steve Simonson from Windtree noted the findings will inform future development strategies for istaroxime.
Windtree Therapeutics has successfully completed its underwritten public offering of 3,686,006 shares of common stock, raising approximately $12.4 million before expenses. Each share was priced at $2.93 and sold alongside a warrant to purchase an additional share. The offering included the underwriter's full option to buy an additional 552,900 shares and warrants. Windtree plans to allocate up to $3.5 million of the net proceeds to extend enrollment and complete a Phase 2 clinical trial for istaroxime, a candidate for treating cardiogenic shock, with the remainder directed towards working capital. The securities were offered under Windtree's registration statement, effective April 19, 2023.
Windtree Therapeutics has announced the pricing for its underwritten public offering, consisting of 3,686,006 shares of common stock and warrants to purchase the same amount. The combined offering price is set at $2.93 per share and accompanying warrant, with an expected gross proceeds of approximately $10.8 million. Proceeds are earmarked primarily for the completion of a Phase 2 clinical trial for istaroxime in cardiogenic shock, with the remainder allocated for working capital. The offering is anticipated to close around April 24, 2023, pending standard closing conditions. Ladenburg Thalmann & Co. Inc. serves as the sole book running manager. Additionally, the underwriter has a 45-day option to purchase up to 552,900 shares or warrants. This offering has been filed with the SEC under Form S-1.
Windtree Therapeutics (NasdaqCM: WINT) announced that the European Patent Office has granted Patent No. 3599243, protecting a class of SERCA2a Activators for heart failure treatment until July 2038. This patent covers dual mechanism drug candidates that both activate SERCA2a and inhibit the Na+/K+ pump. Unlike existing treatments, these candidates may offer both intravenous and oral therapies for acute heart failure and chronic heart failure management.
CEO Craig Fraser highlighted the significance of SERCA2a activation in advancing heart failure treatment. Windtree's platform also includes istaroxime, a first-in-class therapy that improves cardiac function.